US FDA And Sponsors Resolve Disclosure Issues On Complex Trial Design Pilot Projects
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
You may also be interested in...
User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.
FDA Commissioner Hahn says industry needs to work with the agency to establish a link to more detailed supply chain information.
The Center for Biologics Evaluation and Research may need more fee revenue to add employees to handle the increasing cell and gene therapy workload.